新华社布加勒斯特2月27日电近日发表在国际学术期刊《微生物学前沿》上的一项新研究显示，在罗马 尼亚一处数千年历史的冰洞中发现的一种古老细菌对多种现代常用抗生素具有耐药性，表明细菌的耐药 性可以在自然演化中形成。 这种细菌发现于罗马尼亚一处冰洞约5000年前形成的冰层中。罗马尼亚科学院布加勒斯特生物研究所等 机构的研究人员在冰洞中钻取了一根长25米的冰芯，从中分离出多种细菌菌株，并对它们的基因组测序 分析，以研究其耐寒机制以及耐药性相关基因等。 研究人员利用10大类的28种临床常用或储备用抗生素对其中一种名为SC65A.3的嗜冷菌菌株进行测试， 发现它对其中的10种抗生素表现出耐药性，包括利福平、万古霉素和环丙沙星等用于治疗常见感染的药 物。SC65A.3也是第一种被发现对甲氧苄啶、克林霉素、甲硝唑等抗生素具有耐药性的嗜冷菌菌株。 研究还发现，SC65A.3携有百余个与耐药性相关的基因，还能抑制多种多重耐药"超级细菌"的生长，并 具备具有生物技术应用潜力的特殊酶活性。 研究人员认为，能够在寒冷环境存活的菌株可能是抗生素耐药性基因的"天然储库"。针对SC65A.3等古 老微生物的研究展现了抗生素耐药性如何在自然环 ...

研究还发现，SC65A.3携有百余个与耐药性相关的基因，还能抑制多种多重耐药"超级细菌"的生长，并 具备具有生物技术应用潜力的特殊酶活性。 研究人员认为，能够在寒冷环境存活的菌株可能是抗生素耐药性基因的"天然储库"。针对SC65A.3等古 老微生物的研究展现了抗生素耐药性如何在自然环境中演化出来，而这远早于现代抗生素的使用。 新华社布加勒斯特2月27日电（记者张改萍）近日发表在国际学术期刊《微生物学前沿》上的一项新研 究显示，在罗马尼亚一处数千年历史的冰洞中发现的一种古老细菌对多种现代常用抗生素具有耐药性， 表明细菌的耐药性可以在自然演化中形成。 这种细菌发现于罗马尼亚一处冰洞约5000年前形成的冰层中。罗马尼亚科学院布加勒斯特生物研究所等 机构的研究人员在冰洞中钻取了一根长25米的冰芯，从中分离出多种细菌菌株，并对它们的基因组测序 分析，以研究其耐寒机制以及耐药性相关基因等。 研究人员利用10大类的28种临床常用或储备用抗生素对其中一种名为SC65A.3的嗜冷菌菌株进行测试， 发现它对其中的10种抗生素表现出耐药性，包括利福平、万古霉素和环丙沙星等用于治疗常见感染的药 物。SC65A.3也是第一种被发现对甲 ...

Core Viewpoint - The article highlights the risks associated with the misuse of medications, particularly the potential for acute kidney injury when multiple drugs are taken simultaneously or inappropriately [1][3]. Group 1: Causes of Kidney Damage - The kidneys function as the body's filter, processing blood to eliminate toxins and produce urine. The use of multiple medications increases the workload on the kidneys, which can lead to failure, especially if some drugs have inherent nephrotoxic properties [3]. - Common medications that pose a risk to kidney health include analgesics like ibuprofen, acetaminophen, and aspirin, particularly when taken in excess or over long periods [5]. - Certain antibiotics, such as aminoglycosides (e.g., gentamicin, kanamycin) and vancomycin, can also directly harm the kidneys if not used correctly [5]. - Some traditional Chinese medicines and folk remedies may contain nephrotoxic ingredients, such as Aristolochia and Guanmuxiang, which can pose hidden risks [6]. Group 2: Recommendations for Kidney Protection - Avoid mixing medications without professional guidance, especially during illness, to prevent overlapping ingredients and potential overdoses [9]. - Carefully read medication instructions, paying attention to warnings regarding kidney function and potential drug interactions [10]. - Inform healthcare providers about any chronic conditions, such as kidney disease, hypertension, or diabetes, to ensure appropriate medication plans are developed [11]. - Maintain adequate hydration while taking medications, as this can help facilitate the elimination of drug metabolites and reduce kidney strain [11]. Group 3: Warning Signs of Kidney Issues - Be vigilant for symptoms such as decreased urine output, swelling in the lower extremities or eyelids, nausea, fatigue, lower back pain, and increased foamy urine, which may indicate kidney problems and necessitate immediate medical attention [12].

Core Insights - A new antibiotic, pre-methenamine C lactone, has been discovered by chemists from the University of Warwick and Monash University, showing over 100 times higher antibacterial activity against various resistant pathogens compared to the known antibiotic methenamine A [1][2] - The discovery was made during the synthesis of methenamine A, where previously untested intermediates exhibited significant antibacterial properties, particularly against MRSA and VRE [1] Group 1 - The new antibiotic demonstrates significant efficacy against MRSA, a superbug resistant to multiple common antibiotics, and VRE, which can resist the strongest antibiotic vancomycin [1] - Pre-methenamine C lactone showed no signs of resistance in enterococci during experiments, unlike vancomycin, which induced resistance under the same conditions [1] - The findings suggest that pre-methenamine C lactone could be a potential new candidate drug for combating VRE infections [1] Group 2 - Pre-methenamine C lactone is characterized by its simple structure, strong activity, low likelihood of developing resistance, and ease of synthesis, positioning it as a promising candidate for a new generation of antibiotics [2] - This discovery offers hope to the approximately 1.1 million people who lose their lives each year due to antibiotic resistance [2]

Core Points - The 2025 National Medical Insurance Directory negotiations have officially commenced, highlighting the importance of pharmaceutical innovation and patient access to medications [1] - The atmosphere at the negotiations is characterized by a cautious and low-key approach from pharmaceutical representatives, with an increased emphasis on confidentiality [3][4] - A total of 535 drugs are under review, with 311 outside the directory and 224 within it, alongside 121 high-value drugs reviewed under the commercial insurance innovation drug directory [9][10] Group 1: Negotiation Atmosphere - The entry process for pharmaceutical representatives was notably quieter and more orderly compared to previous years, reflecting a more subdued approach [3][4] - Representatives from both domestic and multinational pharmaceutical companies, including notable names like 恒瑞医药 and 阿斯利康, participated in the negotiations [4][9] Group 2: Key Drug Categories - Antibacterial drugs are expected to be a significant focus in the afternoon session of the negotiations, with specific products like 万古霉素 being highlighted [9][10] - Innovative drugs, including CAR-T products and new lipid-lowering medications, are also under consideration, with 恒瑞医药 presenting multiple products for initial review [10][12] Group 3: Market Insights - The PCSK9 inhibitor 瑞卡西单抗 has gained attention for its long-acting properties, with a market size of 1.32 billion yuan in 2023, representing 7.8% of the national lipid-lowering drug market [10][11] - The long-acting 阿立哌唑微球 from 丽珠集团 is another product of interest, potentially replacing oral formulations and capturing market share if included in the insurance directory [12]

Core Insights - An international team led by scientists from the University of Liverpool has developed a new antibiotic named Novltex, which shows sustained inhibitory effects against various deadly superbugs, marking significant progress in the fight against antibiotic resistance [1][2] - Antibiotic resistance is listed as one of the top ten health threats to humanity, causing nearly 5 million deaths annually, with the WHO highlighting the urgent need for new antibiotics [1] - Novltex targets lipid II, a crucial component of bacterial cell walls that is less prone to mutation, offering durable resistance protection against antibiotic resistance [1][2] Summary by Sections Development and Testing - Novltex was inspired by the existing antibiotics Teixobactin and Clofazimine, avoiding the use of expensive raw materials and allowing for the construction of numerous candidate molecules for optimization [2] - The antibiotic demonstrates sustained antibacterial capabilities, remaining effective at low doses and outperforming existing antibiotics like Vancomycin and Daptomycin, with no toxicity to human cells [2] Significance and Potential - The combination of efficiency, durability, and scalability makes Novltex one of the most promising antibiotic candidates in decades [2] - The synthetic efficiency of Novltex is reported to be 30 times higher than that of natural products, enhancing its potential for mass production [2]

Core Viewpoint - The article discusses the impact of China's drug procurement policy on pharmaceutical companies, highlighting the shift from a price-cutting competition to a focus on quality and innovation in the industry [2][4][6]. Group 1: Price Competition and Its Consequences - The aggressive price competition in the pharmaceutical industry has led to significant revenue losses, with a total of 48.3 billion yuan cut from the national drug market after four rounds of procurement [2]. - The phenomenon of "price wars" has resulted in extremely low prices for drugs, exemplified by the 0.09 yuan per tablet price for Amlodipine, which is unsustainable for many companies [2][4]. - The intense competition has forced companies to compromise on quality, leading to concerns about supply disruptions and product quality [2][3]. Group 2: New Procurement Rules - The latest round of procurement introduces new rules aimed at curbing the "race to the bottom" in pricing, shifting the focus from "lowest price wins" to "value for money" [3][4]. - A new price difference mechanism has been established, allowing for reasonable price premiums, which requires companies to ensure that their quoted prices do not lead to losses [3][4]. - Quality standards have been tightened, with new regulations mandating that only companies with at least two years of production experience can participate, along with comprehensive inspections of both companies and products [3][4]. Group 3: Focus on Innovation - The new procurement policy allows for the exclusion of high-risk and patented drugs from the procurement process, enabling original branded drugs to compete in public hospitals if they agree to lower prices [4]. - The policy aims to facilitate a market environment where innovative drugs can thrive, with 60% of the savings from procurement being reinvested into innovative drug development [4][6]. - The shift from a focus on generic drugs to innovative solutions is seen as essential for the long-term sustainability of the pharmaceutical industry in China [6].

Core Viewpoint - The article discusses the development of a novel ultrasound-sensitive broad-spectrum antimicrobial peptide based on diphenylalanine, which shows high efficacy against drug-resistant bacteria and offers a promising strategy for treating infections caused by antibiotic-resistant pathogens [1][2][9]. Group 1: Antimicrobial Resistance and Challenges - Overuse of antibiotics has led to an increase in drug-resistant pathogens, making infections harder to treat and posing significant health risks globally [1]. - Traditional antimicrobial peptides (AMPs) have limitations, including slow antibacterial effects, rapid biodegradation, non-selective toxicity, and short retention time at infection sites [4]. Group 2: Research Findings - The research team developed a short peptide that is activated by ultrasound, achieving over 99% antibacterial efficiency against clinical isolates of methicillin-resistant bacteria within 15 minutes of ultrasound exposure, while exhibiting low toxicity [5][6]. - Seven short peptides were designed, with one specific peptide (FFRK8) demonstrating satisfactory antibacterial performance and biocompatibility under ultrasound activation [6]. Group 3: Clinical Implications - In a goat model of difficult-to-treat intervertebral disc infection, FFRK8 outperformed the potent antibiotic vancomycin, indicating its potential for clinical applications [7]. - The study suggests that ultrasound-activated antimicrobial peptides could provide an effective treatment for deep infections with poor vascular distribution, addressing the challenge of antibiotic resistance [9].